These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23999912)

  • 41. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
    Emslie GJ; Wells TG; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical tolerance of a new antidepressant -- milnacipran].
    Regina W; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1999; 25(3):252-8. PubMed ID: 10434151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder.
    Clayton AH; Kornstein SG; Rosas G; Guico-Pabia C; Tourian KA
    CNS Spectr; 2009 Apr; 14(4):183-95. PubMed ID: 19407730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
    Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
    Tummala R; Desai D; Szamosi J; Wilson E; Hosford D; Dunbar G; Eriksson H
    J Clin Psychopharmacol; 2015 Feb; 35(1):77-81. PubMed ID: 25514064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
    Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
    Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
    Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N
    Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duloxetine in the long-term treatment of major depressive disorder.
    Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
    J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
    Lopez-Ibor JJ; Conesa A;
    Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of levomilnacipran extended release in treating major depressive disorder.
    Ragguett RM; Yim SJ; Ho PT; McIntyre RS
    Expert Opin Pharmacother; 2017 Dec; 18(18):2017-2024. PubMed ID: 29195487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
    Atkinson S; Thurman L; Ramaker S; Buckley G; Jones SR; England R; Wajsbrot D
    CNS Spectr; 2019 Oct; 24(5):496-506. PubMed ID: 30419989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.
    Wernicke JF; Raskin J; Rosen A; Pritchett YL; D'Souza DN; Iyengar S; Knopp K; Le TK
    Curr Ther Res Clin Exp; 2006 Sep; 67(5):283-304. PubMed ID: 24678103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
    McIntyre RS; Gommoll C; Chen C; Ruth A
    CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
    J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
    Kornstein SG; Gommoll C; Chen C; Kramer K
    J Affect Disord; 2016 Mar; 193():137-43. PubMed ID: 26773906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.
    Shiovitz T; Greenberg WM; Chen C; Forero G; Gommoll CP
    Innov Clin Neurosci; 2014 Jan; 11(1-2):10-22. PubMed ID: 24653937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Controlled comparison of two different doses of milnacipran in major depressive outpatients.
    Kanemoto K; Matsubara M; Yamashita K; Tarao Y; Inada E; Sekine T
    Int Clin Psychopharmacol; 2004 Nov; 19(6):343-6. PubMed ID: 15486520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.